Patents by Inventor Ulrich Sensfuss
Ulrich Sensfuss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140031278Abstract: The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: March 28, 2012Publication date: January 30, 2014Applicant: NOVO NORDISK A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Thomas Nylandsted Krogh, Ulrich Sensfuss
-
Publication number: 20130288958Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: July 9, 2013Publication date: October 31, 2013Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Patent number: 8541368Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: September 21, 2012Date of Patent: September 24, 2013Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Publication number: 20130012432Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: February 28, 2011Publication date: January 10, 2013Applicant: Novo Nordisk A/SInventors: Kilian Waldemar Conde-Frieboes, Jane Spetzler, Ulrich Sensfuss, Birgitte Schjellerup Wulff, Henning Thoegersen, Jens Christian Norrild
-
Publication number: 20120184487Abstract: The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.Type: ApplicationFiled: June 29, 2010Publication date: July 19, 2012Applicant: Novo Nordisk A/SInventors: Thomas Hoeg-Jensen, Palle Jakobsen, Ulrich Sensfuss, Christian Fledelius, Ulla Ribel-Madsen
-
Publication number: 20120021973Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 24, 2009Publication date: January 26, 2012Applicant: Novo Nordisk A/SInventors: Jesper F. Lau, Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Birgitte Schjellerup Wulff
-
Publication number: 20110098213Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 4, 2005Publication date: April 28, 2011Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Leif Chritensen, Kilian Waldemar Conde Frieboes, Ingrid Pettersson
-
Publication number: 20100173835Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 25, 2009Publication date: July 8, 2010Applicant: Novo Nordisk A/SInventors: Jesper Lau, Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Birgitte Schjellerup Wulff
-
Publication number: 20100056433Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: January 17, 2008Publication date: March 4, 2010Applicant: Novo Nordisk A/SInventor: Ulrich Sensfuss
-
Publication number: 20100016237Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: January 17, 2008Publication date: January 21, 2010Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Jane Spetzler
-
Publication number: 20100016238Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: January 17, 2008Publication date: January 21, 2010Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Jesper Lau
-
Publication number: 20090203581Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: July 7, 2006Publication date: August 13, 2009Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Leif Christensen, Jane Spetzler, Kilian Waldemar Conde Frieboes, Henning Thogersen
-
Patent number: 7541430Abstract: Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.Type: GrantFiled: November 7, 2005Date of Patent: June 2, 2009Assignee: Novo Nordisk A/SInventors: Ulrich Sensfuss, Kilian Waldemar Conde Frieboes, Leif Christensen, Ingrid Vivika Petterson, Thomas Kruse Hansen, Michael Ankersen, Kjeld Madsen
-
Patent number: 7517854Abstract: Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.Type: GrantFiled: March 30, 2006Date of Patent: April 14, 2009Assignee: Novo Nordisk A/SInventors: Kilian Waldemar Conde-Frieboes, Ulrich Sensfuss, Kjeld Madsen, Nils Langeland Johansen, Leif Christensen, Thomas Kruse Hansen, Birgitte Schjellerup Wulff
-
Publication number: 20090088388Abstract: Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.Type: ApplicationFiled: July 8, 2008Publication date: April 2, 2009Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Kilian Waldemar Conde Frieboes, Leif Christensen, Ingrid Vivika Petterson, Thomas Kruse Hansen, Michael Ankersen, Kjeld Madsen
-
Publication number: 20080306008Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 4, 2005Publication date: December 11, 2008Applicant: Nova Nordisk A/SInventors: Ulrich Sensfuss, Leif Christensen
-
Publication number: 20080280820Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 4, 2005Publication date: November 13, 2008Inventors: Ulrich Sensfuss, Leif Christensen
-
Publication number: 20080039387Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 4, 2005Publication date: February 14, 2008Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Kilian Conde Frieboes
-
Publication number: 20070244054Abstract: Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.Type: ApplicationFiled: November 7, 2005Publication date: October 18, 2007Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Kilian Conde Frieboes, Leif Christensen, Ingrid Petterson, Thomas Hansen, Michael Ankersen, Kjeld Madsen
-
Publication number: 20070185128Abstract: Described herein are novel and useful compounds of the general formula Compounds of this invention can advantageously exhibit melanocortin receptor agonist activity. New and useful compounds comprising such a chemical structure and methods of modulating melanocortin receptor activity in a subject (and promoting, inducing, and/or enhancing the treatment or prevention of related diseases) by administering such a compound or composition also are described.Type: ApplicationFiled: November 21, 2003Publication date: August 9, 2007Inventors: Kilian Conde-Frieboes, Michael Ankersen, Ulrich Sensfuss, Birgitte Wulff, Henning Thogersen, Philipp Lustenberger, Klaus Rudolf, Bernd Krist, Stephan Muller, Dirk Stenkamp, Marcus Schindler, Heike Wieland, Kirsten Arndt